» Articles » PMID: 26317340

A Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human Lung

Overview
Journal PLoS One
Date 2015 Aug 29
PMID 26317340
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary arterial hypertension (PAH) is a vascular disease characterized by persistent precapillary pulmonary hypertension (PH), leading to progressive right heart failure and premature death. The pathological mechanisms underlying this condition remain elusive. Analysis of global metabolomics from lung tissue of patients with PAH (n = 8) and control lung tissue (n = 8) leads to a better understanding of disease progression. Using a combination of high-throughput liquid-and-gas-chromatography-based mass spectrometry, we showed unbiased metabolomic profiles of disrupted arginine pathways with increased Nitric oxide (NO) and decreased arginine. Our results also showed specific metabolic pathways and genetic profiles with increased Sphingosine-1-phosphate (S1P) metabolites as well as increased Heme metabolites with altered oxidative pathways in the advanced stage of the human PAH lung. The results suggest that PAH has specific metabolic pathways contributing to the vascular remodeling in severe pulmonary hypertension. Profiling metabolomic alterations of the PAH lung has provided a new understanding of the pathogenic mechanisms of PAH, which benefits therapeutic targeting to specific metabolic pathways involved in the progression of PAH.

Citing Articles

Interplay of Transcriptomic Regulation, Microbiota, and Signaling Pathways in Lung and Gut Inflammation-Induced Tumorigenesis.

Otalora-Otalora B, Payan-Gomez C, Lopez-Rivera J, Pedroza-Aconcha N, Arboleda-Mojica S, Aristizabal-Guzman C Cells. 2025; 14(1.

PMID: 39791702 PMC: 11720097. DOI: 10.3390/cells14010001.


Exercise improves systemic metabolism in a monocrotaline model of pulmonary hypertension.

Poojary G, Vasishta S, Thomas R, Satyamoorthy K, Padmakumar R, Joshi M Sports Med Health Sci. 2024; 7(1):37-47.

PMID: 39649790 PMC: 11624410. DOI: 10.1016/j.smhs.2024.03.001.


Identification of TFRC as a biomarker for pulmonary arterial hypertension based on bioinformatics and experimental verification.

Yang C, Liu Y, Zheng H Respir Res. 2024; 25(1):296.

PMID: 39097701 PMC: 11298087. DOI: 10.1186/s12931-024-02928-6.


Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics.

Ba H, Guo Y, Jiang Y, Li Y, Dai X, Liu Y Respir Res. 2024; 25(1):221.

PMID: 38807129 PMC: 11131231. DOI: 10.1186/s12931-024-02775-5.


Neutrophil extracellular traps promote proliferation of pulmonary smooth muscle cells mediated by CCDC25 in pulmonary arterial hypertension.

Sun H, Du Z, Zhang X, Gao S, Ji Z, Luo G Respir Res. 2024; 25(1):183.

PMID: 38664728 PMC: 11046914. DOI: 10.1186/s12931-024-02813-2.


References
1.
Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G . Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med. 2010; 10:22. PMC: 2873470. DOI: 10.1186/1471-2466-10-22. View

2.
Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes K, Lopaschuk G . Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010; 2(44):44ra58. DOI: 10.1126/scitranslmed.3001327. View

3.
Closs E . Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens. 2001; 11(1):99-107. DOI: 10.1097/00041552-200201000-00015. View

4.
Thomas M . Pharmacological targets for pulmonary vascular disease: vasodilation versus anti-remodelling. Adv Exp Med Biol. 2010; 661:475-90. DOI: 10.1007/978-1-60761-500-2_31. View

5.
Balint B, Kharitonov S, Hanazawa T, Donnelly L, Shah P, Hodson M . Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. Eur Respir J. 2001; 17(6):1201-7. DOI: 10.1183/09031936.01.00072501. View